ArticleMethods in enzymology2014
The use of mitochondria-targeted endonucleases to manipulate mtDNA.
Article in Methods in enzymology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Adeno-Associated virus-based approaches for mitochondrial diseases: advances and challenges.Molecular psychiatry · 2026Review
- Heterogeneous brain region-specific responses to astrocytic mitochondrial DNA damage in mice.Scientific reports · 2024Article
- Induce male sterility by CRISPR/Cas9-mediated mitochondrial genome editing in tobacco.Functional & integrative genomics · 2023Article
- Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges.Nature reviews. Neurology · 2022Review
- Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?International journal of molecular sciences · 2021Review
- Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo.Nature communications · 2021Article
- Potential of Mitochondrial Genome Editing for Human Fertility Health.Frontiers in genetics · 2021Review
- Adapting CRISPR/Cas9 System for Targeting Mitochondrial Genome.Frontiers in genetics · 2021Article
- Visualizing, quantifying, and manipulating mitochondrial DNA in vivo.The Journal of biological chemistry · 2020Review
- Stable retention of chloramphenicol-resistant mtDNA to rescue metabolically impaired cells.Scientific reports · 2020Article
- DNA-editing enzymes as potential treatments for heteroplasmic mtDNA diseases.Journal of internal medicine · 2020Review
- Mapping and editing animal mitochondrial genomes: can we overcome the challenges?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2020Review
- Energetic costs of cellular and therapeutic control of stochastic mitochondrial DNA populations.PLoS computational biology · 2019Article
- Diagnosis and Treatment of Mitochondrial Myopathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- Advances in methods for reducing mitochondrial DNA disease by replacing or manipulating the mitochondrial genome.Essays in biochemistry · 2018Review
- Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing.Physiological reviews · 2018Review
- Inherited mitochondrial genomic instability and chemical exposures.Toxicology · 2017Review
- Human mitochondrial nucleases.The FEBS journal · 2017Review
- Article
- MitoTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
For more than a decade, mitochondria-targeted nucleases have been used to promote double-strand breaks in the mitochondrial genome. This was done in mitochondrial DNA (mtDNA) homoplasmic systems, where all mtDNA molecules can be affected, to create models of mitochondrial deficiencies. Alternatively, they were also used in a heteroplasmic model, where only a subset of the mtDNA molecules were substrates for cleavage. The latter approach showed that mitochondrial-targeted nucleases can reduce mtDNA haplotype loads in affected tissues, with clear implications for the treatment of patients with mitochondrial diseases. In the last few years, designer nucleases, such as ZFN and TALEN, have been adapted to cleave mtDNA, greatly expanding the potential therapeutic use. This chapter describes the techniques and approaches used to test these designer enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.